| Description | Human CD14 knockout MDA-MB-361 cell line is edited by our special CRISPR/Cas9 technology. The cell line was from a 40-year-old woman with breast cancer, but the cells were isolated from metastatic sites in the brain. |
| Size | 1 vial (2*106 cells/vial) |
| Parental Cell Line | MDA-MB-361 |
| Biosafety Level | 1 |
| Format | Frozen |
| Culture Conditions | Cells are adherent cells that are cultured at 37℃ in air. |
| Culture Medium | L-15 + 2mM Glutamine + 15% FBS |
| Subculture Conditions | Split confluent cultures 1:3 to 1:6, i.e. seeding at 3-6*10,000 cells/cm2 using 0.25% trypsin or trypsin/EDTA; 37°C. CO2 is not required. |
| Derived From | Human breast (brain metastasis) |
| Knockout Validation | Sanger Sequencing |
| Viability | >95% viability before freezing. |
| Adherent /Suspension | Adherent |
| Disease | Adenocarcinoma |
| Purity | Immunogen affinity purified |
| Storage | Vapor phase of liquid nitrogen |
| Sterility | Mycoplasma negative, HOECHST and PCR |
| Shipping Info | Dry Ice |
| Species | Human |
| Tested Applications | Suitable for: ICC, WB, Sanger Sequencing |
| Tissue | Breast; Mammary gland |
| Recommended Control | Human wild-type MDA-MB-361 cell line |
| Morphology | Epithelial |
| Pathogens | HIV: Negative Hepatitis B: Negative Hepatitis C: Negative |
| Applications | For research use only |
| Product Type | Knockout Stable Cell Line |
| Price | Inquiry |
